A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis
J. Koo, B. Abrams, G. Albrecht, P. Altmeyer, F. A. Bahmer, S. Belaich, J. Berth-Jones, J. R. Bjerke, J. D. Bos, L. Braathen, G. Burg, D. Burrows, A. Claudy, L. A. Drake, L. Dubertret, R. Engst, M. I. Ettelt, E. Frenk, P. J. Frosch, J. GanslandtM. Goos, R. A.C. Graham-Brown, J. J. Guilhou, U. F. Haustein, S. Helland, K. Hutchinson, H. Jacobi, E. G. Jung, S. Kang, P. Kind, J. Knop, N. J. Lowe, T. Luger, G. Mahrle, R. Marks, H. Meffert, J. Meyer, N. J. Mørk, U. Mrowietz, H. A.M. Neumann, E. A. Olsen, S. Rogers, T. Ruzicka, A. G. Schmidt, E. Schöpf, J. L. Shupack, T. M. Starink, D. Tio, W. A. Van Vloten, B. J. Vermeer, U. Wollina
Research output: Contribution to journal › Article › peer-review
105Scopus
citations
Fingerprint
Dive into the research topics of 'A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis'. Together they form a unique fingerprint.